1. Short title This Act may be cited as the Advancing Innovation in Alternative Pain and Addiction Therapies Act . 2. Accelerated approval of pain and addiction therapies (a) Purpose It is the purpose of this section to clarify the appropriate processes for encouraging and expediting the review of non-opioid or non-addictive medical products to treat chronic or acute pain or substance use disorders. (b) Draft guidance (1) In general Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ), acting through the Commissioner of Food and Drugs, shall issue draft guidance, clarifying the methods and processes by which the Food and Drug Administration may provide accelerated approval for non-opioid or non-addictive drugs developed to treat chronic or acute pain or substance use disorders. (2) Contents The guidance under paragraph (1) shall address— (A) eligibility requirements for such drugs to receive accelerated approval; (B) opportunities for engagement with the Food and Drug Administration with respect to the accelerated approval pathway; (C) considerations for different types of pain and product mechanism of action